Form 4: Esperion Therapeutics CEO Sells Shares to Cover Tax Obligations

Esperion Therapeutics' President and CEO, Sheldon L. Koenig, sold 30,474 shares of common stock to satisfy tax obligations related to vested restricted stock units.

Summary

• Sheldon L. Koenig, President and CEO, and a Director of Esperion Therapeutics, Inc. (ESPR), reported a sale of common stock.
• On June 17, 2025, Mr. Koenig disposed of 30,474 shares of Esperion Therapeutics common stock.
• The shares were sold at a price of $1.109 per share.
• The purpose of the sale was to satisfy tax obligations arising from the vesting of restricted stock units.
• Following this transaction, Mr. Koenig beneficially owns 1,541,488 shares of common stock directly.

Sentiment

Score: 5

Explanation: The transaction is a routine, non-discretionary sale to cover tax obligations on vested equity, which is a common practice and generally does not reflect a change in management's outlook on the company. It's neutral in sentiment.

Positives

• The transaction is a non-discretionary sale, indicating it is not a signal of lack of confidence in the company's future.
• The CEO still retains a significant number of shares (1,541,488), maintaining alignment with shareholder interests.

Negatives

• The sale reduces the direct beneficial ownership of the CEO by 30,474 shares.

Stakeholder Impact

• Shareholders: A slight reduction in direct insider ownership, but the non-discretionary nature of the sale mitigates concerns about management confidence.

Key Dates

Recommendation

Keywords

Esperion Therapeutics, ESPR, Sheldon L. Koenig, Insider Trading, Form 4, Stock Sale, Tax Obligation, Restricted Stock Units, CEO, Director